Company intelligence / Profile preview

Shanghai Ming Ju Biotechnology

Shanghai, Shanghai, Chinajwtherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Shanghai Ming Ju Biotechnology, as part of JW Therapeutics, has developed Carteyva® (relmacabtagene autoleucel), an autologous anti-CD19 CAR-T cell immunotherapy. Carteyva® is approved in China for follicular and mantle-cell lymphomas, with ongoing clinical trials in other hematologic malignancies and autoimmune diseases such as SLE. The company has a robust pipeline focused on both hematological cancers and solid tumors, leveraging a fully integrated platform for product development, manufacturing, and commercialization.

Therapeutic areas: OncologyImmunology
Modalities: CAR-T cell therapyGene therapyImmunotherapyAutologous CAR-T cell therapy
Industry: Biotech

Partnerships

Juno Therapeutics/Bristol Myers Squibb

Beyond the preview

Go deeper on Shanghai Ming Ju Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Ming Ju Biotechnology.